MRC Technology Appoints Two New Members to Board of Trustees
News Apr 07, 2016
MRC Technology aims to find new treatments in areas where there is unmet patient need. It works with academic, biotechnology, pharmaceutical and charity organisations to find science with potential and develop it to improve diagnostics and medicines. Current board members have been selected for their extensive experience across the biomedical sciences, finance, investment fund management, law and medicine, in order to support strategic direction and delivery of the organisation’s charitable objects.
Dr John Stageman, Chairman, MRC Technology, commented: “As a charity we strive to ensure that innovative science in any disease area reaches its full potential. Our board of trustees plays a vital role in governing the charity and we are therefore delighted to welcome Les and Mike who together bring huge additional experience in life sciences research and development, and related industry knowledge.”
Dr Les Hughes’ experience in the pharmaceutical industry spans over 30 years, initially as a medicinal chemist followed by roles leading drug discovery projects and programmes across a number of therapeutic areas. He was elected a Fellow of the Academy of Medical Sciences in 2003.
Dr Mike Romanos has been involved in the biotech and pharmaceutical industry for over 30 years, with experience covering most areas of drug discovery science and technology, and several therapeutic areas, as well as experience in shaping IP strategy and gaining and defending valuable patents.
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Biomarkers Could Produce Preeclampsia Diagnostic TestNews
Small non-coding RNA analysis may revolutionize how doctors assess preeclampsia risk.READ MORE